NASDAQ:AMAM - Nasdaq - US6418711080 - Common Stock - Currency: USD
NEW AMBRX BIOPHARMA INC
NASDAQ:AMAM (3/6/2024, 8:00:01 PM)
After market: 28 0 (0%)28
+0.02 (+0.07%)
The current stock price of AMAM is 28 USD. In the past month the price increased by 0.79%. In the past year, price increased by 188.96%.
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders...
Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount.
Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays.
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.77 | 335.67B | ||
AMGN | AMGEN INC | 15.04 | 155.36B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
NTRA | NATERA INC | N/A | 23.00B | ||
BIIB | BIOGEN INC | 8.73 | 20.76B | ||
UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Ambrx Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). The company uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.
NEW AMBRX BIOPHARMA INC
10975 North Torrey Pines Road
La Jolla CALIFORNIA US
CEO: Feng Tian
Employees: 66
Company Website: https://ambrx.com/
Phone: 18588752400
The current stock price of AMAM is 28 USD.
The exchange symbol of NEW AMBRX BIOPHARMA INC is AMAM and it is listed on the Nasdaq exchange.
AMAM stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AMAM, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AMAM.
AMAM does not pay a dividend.
AMAM will report earnings on 2024-03-26.
AMAM does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.57).
ChartMill assigns a technical rating of 10 / 10 to AMAM. When comparing the yearly performance of all stocks, AMAM is one of the better performing stocks in the market, outperforming 98.51% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to AMAM. AMAM has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months AMAM reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by -16% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -30.43% | ||
ROE | -34.09% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 76% to AMAM. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -159.66% and a revenue growth -57.14% for AMAM